In various embodiments methods of producing a cell population enriched for CLEC9A+ dendritic cells are provided where the methods involve culturing stem cells and/or progenitor cells in a cell culture comprising culture medium, a notch ligand, stem cell factor (SCF), FLT3 ligand (FLT3L); thrombopoietin (TPO); and IL-3 and/or GMCSF.

The invention provides means, methods and some compositions of matter useful to treat ovarian failure. In one embodiment progenitor cells possessing ability to differentiate along the monocytic and granulocyte linages are utilized as a source of cytokines for stimulation of ovarian repair/regeneration. Generation of said cells, such as classically termed myeloid derived suppressor cells is performed from sources including cord blood, bone marrow, mobilized peripheral blood and pluripotent stem cells. The invention further provides means of suppressing fibrosis and ongoing inflammation associated with ovarian dysfunction.

The present invention provides compositions and methods for the regeneration of tissue. In particular, the present invention provides mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs) for bladder regeneration.

Aspects of the invention relate to a novel mesenchymal stem cell line (hb-MSC), a culture medium conditioned by the hb-MSC line, and various hb-MSC compositions. The hb-MSC compositions may include a plurality of hb-MSCs, the hb-MSC conditioned medium, or a combination thereof. The hb-MSC compositions may also include one or more of an antimicrobial agent, a film-forming agent, an appropriate carrier, as well as other additives as determined by the application. Also described are methods of use for the hb-MSC cells, the conditioned medium, and the compositions, including methods of treating or preventing bovine mastitis.

The current invention concerns a cell medium for in vitro inducing chondrogenesis or tenogenesis in mesenchymal stem cells (MSCs). The medium includes a glucose medium supplemented with at least one growth factor. The growth factor is selected from fibroblast growth factors (FGF) or transforming growth factors (TGF). FGF or TGF is present in a total concentration of between 1 and 15 ng/ml. In both cases, IGF can be added to enhance the induction process. In a further aspect, the invention provides for a use of such cell medium as well as a method for inducing isolated mesenchymal stem cells (MSCs) and a cell composition obtained by such method.

Stem cell conditioned media and methods of producing the same to treat mammalian injuries or insults. In at least one embodiment of a method of producing a stem cell conditioned media of the present disclosure, the method comprises the steps of culturing at least one stem cell in a first cell culture medium, replacing some or all of the first cell culture medium with a second cell culture medium and further culturing the at least one stem cell in the second cell culture medium, and collecting a quantity of the second cell culture medium after a culture duration, wherein the quantity of the second cell culture medium contains a cell culture byproduct effective to treat a mammalian insult or injury. A stem cell culture supernatant containing at least one factor capable of exerting effective neuroprotection to treat a mammalian neural injury or insult.

Improved hybrid neurovascular spheroids and methods for making the same are provided. In some embodiments of a method for making a hybrid neurovascular spheroid, the method includes i) propagating cortical cells to form a cortical spheroid; ii) propagating endothelial cells to form an endothelial spheroid; iii) propagating mesenchymal stem cells to form a mesenchymal cell culture; and iv) combining the cortical spheroid, endothelial spheroid, and mesenchymal spheroid under conditions to form the hybrid neurovascular spheroid.

The presently disclosed subject matter is to provide a hepatocyte structure, particularly, a hepatocyte structure that mimics nonalcoholic steatohepatitis (NASH).

A hepatocyte construct including an aggregate containing hepatocytes and adherent cells that are non-hepatocytes, and wherein the hepatocytes include ballooned hepatocytes is provided. Further, a method for producing a hepatocyte construct, comprising: (i) forming an aggregate by aggregating a cell group comprising hepatocytes and adherent cells that are non-hepatocytes; and (ii) culturing the aggregate is provided.

The present invention provides a culture method for culturing, in recesses (10), a population including two or more cells including a cell derived from a stem cell and a mesenchymal cell. The cell derived from a stem cell is a cell obtained by differentiating a stem cell in vitro. The cell is a cell of one or more types selected from the group consisting of an endodermal cell, an ectodermal cell, and a mesodermal cell. The population is cultured in the recesses (10) together with a vascular cell or a secretor factor. Each recess (10) includes a space in which cells are movable. When a volume of the space is represented by V mm.sup.3 and the number of mesenchymal cells seeded in the space is represented by N, V is 400 or less and N/V is in a range from 35 to 3000.

The present invention provides a system for artificially inducing and regulating tissue interactions among multiple tissues. A construct for transplantation into a living body, which comprises a structure and a cell mass linked to each other, the structure being an object having a three-dimensional structure and capable of mimicking or resembling a structure and/or a function of the living body.